Vanguard Small-Cap Growth ETF
Analyzing BEAT, SUPN, ADBE And RHT Stocks
Growth stock analysis BioTelemetry BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market […]
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
Inside Analysts’ Recommendations for Novavax in November 2017
A clinical-stage biotech company, Novavax’s (NVAX) pipeline includes products for influenza, Ebola virus, and Zika virus. In November, two of seven analysts gave NVAX stock a “strong buy” rating.
Alnylam Saw Serious Adverse Event in Fitusiran Phase 2 OLE Study
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had suspended all of its fitusiran studies after a serious adverse event (or SAE).
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
Understanding Abiomed’s Changing Payment Structure Plans for Impella
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
Understanding Align Technology’s Growing Position in International Markets
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
Inside Exelixis’s Robust Growth Strategy for Cabometyx
Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.
Vail Resorts: Exceptional Takes Time, According to Baron
Baron Capital began investing in Vail Resorts in 1997, and it owns a ~15%–20% stake in the company. According to Ron Baron, this investment has returned ~50%–75%.
How Does GNC Holdings Compare with Its Peers?
GNC Holdings has mostly outperformed its peers, based on its price-to-sales ratio.
4Q15: How Did GNC Holdings’ Segments Perform?
GNC Holdings (GNC) reported revenue of $618.2 million, a rise of 1.8% over the corresponding period last year.